---
category: news
title: "BioXcel Therapeutics Announces BXCL501 Met the Primary and All Secondary Endpoints in the ..."
excerpt: "Statistically significant, clinically meaningful, rapid and durable reductions in agitation achieved with the 60 mcg dose as measured by multiple agitation scales BXCL501 was well tolerated with no severe or serious adverse events Results provide a clear path toward initiating a pivotal program for BXCL501 in dementia Agitation associated with dementia affects an estimated 4 million patients in the U."
publishedDateTime: 2021-01-06T10:11:00Z
originalUrl: "https://apnews.com/press-release/globenewswire-mobile/business-products-and-services-mental-health-drug-approvals-coronavirus-pandemic-6f9dfb70d355870d0943ac2f58d57a6d"
webUrl: "https://apnews.com/press-release/globenewswire-mobile/business-products-and-services-mental-health-drug-approvals-coronavirus-pandemic-6f9dfb70d355870d0943ac2f58d57a6d"
type: article
quality: 13
heat: 13
published: false

provider:
  name: Associated Press
  domain: apnews.com

topics:
  - AI in Healthcare
  - AI

images:
  - url: "https://apnews.com/images/PaidContent3.png"
    width: 700
    height: 450
    isCached: true

secured: "XQ/K1zNTHGwzFdbc7oSgy0yYqH6rdXvEhQa7H7Qb40kD1vPwfJNboojKRPzPRxJTizA9mVNsNOvbybOimDxxtXKa7v0b1lDQl7cDlvgYJM/fRJ8FpBs0OsbZKJYYi0D5xoToB4snvnG1AdVjd2iEesvFh8uX/spTs3z8gUF2yIgrvEQQajegmAgTLAycHPQ5OhnrqBYvt1F8VBX+3nPQhY4DrYbtUGEzBuQ/g98Cq5M5NY4XeouxirPow/mNfwaGu87/s4iGQCnhvPiu7KzkGmy875FRJ3nr3S+X23Yf0SDFpGKEfsDTn96UU6mr+OqOVhr1IY9SHcNA8bTICTMwEVEWSRyEXbwYU4F3UwM/aLg=;K98t3jwaKojS6rWOwMQ5pg=="
---

